{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:26:16Z","timestamp":1793895976111,"version":"4.8.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ijcard.2026.134668","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T14:54:38Z","timestamp":1783781678000},"page":"134668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["SGLT2 inhibitors and cardiovascular outcomes in patients with diabetes following hematopoietic stem cell transplantation: A propensity-matched cohort study"],"prefix":"10.1016","volume":"461","author":[{"given":"Yong Hao","family":"Yeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermon Kha Kin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia Yi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tze Ern","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravinthan","family":"Vignarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thai Hau","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishanthi","family":"Vigneswaramoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Donisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadi","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tochukwu M.","family":"Okwuosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S.","family":"Hayek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2026.134668_bb0005","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1182\/blood-2012-06-437178","article-title":"Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease","volume":"120","author":"Armenian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ijcard.2026.134668_bb0010","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001220","article-title":"Cardiovascular management of patients undergoing hematopoietic stem cell transplantation: from pretransplantation to survivorship: a scientific statement from the American Heart Association","volume":"149","author":"Hayek","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2026.134668_bb0015","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jaccao.2023.07.007","article-title":"Cardiovascular events after hematopoietic stem cell transplant: incidence and risk factors","volume":"5","author":"Vasbinder","year":"2023","journal-title":"JACC CardioOncol."},{"key":"10.1016\/j.ijcard.2026.134668_bb0020","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134668_bb0025","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134668_bb0030","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jchf.2023.08.026","article-title":"SGLT2 inhibitor use and risk of clinical events in patients with cancer therapy-related cardiac dysfunction","volume":"12","author":"Avula","year":"2024","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.ijcard.2026.134668_bb0035","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jchf.2022.03.006","article-title":"Sodium-glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines","volume":"10","author":"Gongora","year":"2022","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.ijcard.2026.134668_bb0040","first-page":"1319","article-title":"Cardiovascular, diabetes, and cancer strips: evidences, mechanisms, and classifications","volume":"6","author":"Hu","year":"2014","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.ijcard.2026.134668_bb0045","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2026.134668_bb0050","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134668_bb0055","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134668_bb0060","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2026.134668_bb0065","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/ejhf.1732","article-title":"Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium-glucose cotransporter 2 inhibitors","volume":"22","author":"Packer","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2026.134668_bb0070","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.1991.9.7.1215","article-title":"Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens","volume":"9","author":"Braverman","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijcard.2026.134668_bb0075","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1186\/s13287-020-01984-1","article-title":"Melphalan induces cardiotoxicity through oxidative stress in cardiomyocytes derived from human induced pluripotent stem cells","volume":"11","author":"Liu","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.ijcard.2026.134668_bb0080","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann. Intern. Med."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527326005188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527326005188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:46:59Z","timestamp":1793893619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527326005188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":16,"alternative-id":["S0167527326005188"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2026.134668","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 inhibitors and cardiovascular outcomes in patients with diabetes following hematopoietic stem cell transplantation: A propensity-matched cohort study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2026.134668","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"134668"}}